enzyme engineering firm pivots to RNAi stock By Investing.com
Codexis , Inc. (NASDAQ:), a leader in enzyme engineering, has recently pivoted its focus towards the rapidly growing market of RNAi therapeutics. This strategic shift, centered around the company’s innovative ECO Synthesis manufacturing platform, has caught the attention of investors and analysts alike. As Codexis approaches several key inflection points, it’s crucial to examine the company’s potential in this new arena and the challenges it may face.
Strategic Pivot to ECO Synthesis Platform
Codexis has made a significant strategic decision to redirect its efforts towards the development of its ECO Synthesis manufacturing platform. This platform is designed for the commercial-scale manufacturing of RNAi therapeutics through an…
